PTWO vs. SHLT, TOI, NVNO, TIL, SLS, LABP, DTIL, RLYB, TKNO, and FHLT
Should you be buying Pono Capital Two stock or one of its competitors? The main competitors of Pono Capital Two include SHL Telemedicine (SHLT), Oncology Institute (TOI), enVVeno Medical (NVNO), Instil Bio (TIL), SELLAS Life Sciences Group (SLS), Landos Biopharma (LABP), Precision BioSciences (DTIL), Rallybio (RLYB), Alpha Teknova (TKNO), and Future Health ESG (FHLT). These companies are all part of the "medical" sector.
Pono Capital Two (NASDAQ:PTWO) and SHL Telemedicine (NASDAQ:SHLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
60.8% of Pono Capital Two shares are owned by institutional investors. Comparatively, 20.1% of SHL Telemedicine shares are owned by institutional investors. 63.9% of Pono Capital Two shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
SHL Telemedicine has a consensus target price of $11.00, indicating a potential upside of 163.79%. Given SHL Telemedicine's higher possible upside, analysts plainly believe SHL Telemedicine is more favorable than Pono Capital Two.
SHL Telemedicine received 1 more outperform votes than Pono Capital Two when rated by MarketBeat users.
SHL Telemedicine's return on equity of 0.00% beat Pono Capital Two's return on equity.
In the previous week, Pono Capital Two had 3 more articles in the media than SHL Telemedicine. MarketBeat recorded 3 mentions for Pono Capital Two and 0 mentions for SHL Telemedicine. Pono Capital Two's average media sentiment score of 0.33 beat SHL Telemedicine's score of 0.00 indicating that Pono Capital Two is being referred to more favorably in the media.
Pono Capital Two has higher earnings, but lower revenue than SHL Telemedicine.
Summary
Pono Capital Two beats SHL Telemedicine on 6 of the 11 factors compared between the two stocks.
Get Pono Capital Two News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTWO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTWO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pono Capital Two Competitors List
Related Companies and Tools
